Search Results - "Runglodvatana, Yotsawaj"

ARC-10: A phase 3 study to evaluate zimberelimab + domvanalimab versus pembrolizumab in front-line, PD-L1-high, locally advanced or metastatic non–small-cell lung cancer by Chouaid, Christos, Ho, Gwo Fuang, Runglodvatana, Yotsawaj, He, Xian, Ahlers, Christoph Matthias, Pomponio, Debbie, Todd, Trever, Dang, Thao, Naidoo, Jarushka

“…TPS9148 Background: Despite improvements in the management of locally advanced or metastatic non–small cell lung cancer (NSCLC) from programmed cell…”
Get full text

Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC by Lu, Shun, Kato, Terufumi, Dong, Xiaorong, Ahn, Myung-Ju, Quang, Le-Van, Soparattanapaisarn, Nopadol, Inoue, Takako, Wang, Chih-Liang, Huang, Meijuan, Yang, James Chih-Hsin, Cobo, Manuel, Özgüroğlu, Mustafa, Casarini, Ignacio, Khiem, Dang-Van, Sriuranpong, Virote, Cronemberger, Eduardo, Takahashi, Toshiaki, Runglodvatana, Yotsawaj, Chen, Ming, Huang, Xiangning, Grainger, Ellie, Ghiorghiu, Dana, van der Gronde, Toon, Ramalingam, Suresh S.

“…Among patients with EGFR -mutated lung cancer after chemoradiotherapy, 65% of patients who received osimertinib were alive without progression at 2 years, as…”
Get full text